[시장보고서]항정신병약 시장 : 규모, 점유율, 동향 분석, 질환별, 약제별, 치료분류별, 유통채널별, 지역별, 부문 예측(2025-2033년)

항정신병약 시장 : 규모, 점유율, 동향 분석, 질환별, 약제별, 치료분류별, 유통채널별, 지역별, 부문 예측(2025-2033년)

Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Disease (Schizophrenia, Bipolar Disorder), By Drug, By Therapeutic Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1869957

리서치사 : Grand View Research

발행일 : 2025년 10월

페이지 정보 : 영문 110 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,876,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,368,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,351,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

항정신병약 시장 요약

세계의 항정신병약 시장 규모는 2024년에 175억 3,000만 달러로 평가되었고, 2033년까지 322억 4,000만 달러에 이를 것으로 예측됩니다.

2025년부터 2033년까지 연평균 복합 성장률(CAGR) 6.1%로 성장할 전망입니다. 이 시장의 확대는 정신 질환의 유병률 증가, 인지도 향상 및 기술 혁신으로 인한 것입니다. 정부 지원, 보험 적용 범위 확대, 제네릭 의약품의 보급이 특히 신흥 시장에서 접근성을 더욱 촉진하고 있습니다.

항정신병 약물은 정신병과 관련된 증상을 완화하는 데 일반적으로 사용됩니다. 항정신병약은 망상이나 환청(목소리를 듣는 것)을 포함한 다양한 증상을 효과적으로 경감·관리할 수 있습니다. 항정신병약는 뇌에서 도파민과 다른 신경전달물질의 활성을 억제함으로써 작용합니다. 현재 1세대 및 2세대 항정신병 약물이 시장에서 이용 가능합니다.

정신병성 장애의 유병률 증가는 항정신병약 업계 수요 증가를 견인할 것으로 예측됩니다. 정신분열증의 이환율은 일관되게 남성이 여성보다 높고 지역 평균 수명이 연장됨에 따라 정신분열증의 전반적인 부담이 더욱 증가할 것으로 예측됩니다. 고령화도 수요를 지지하는 요인이며, 치매 관련 정신병 등의 증상이 보다 일반적이 되기 때문입니다. 신규 제제나 신규 작용기전을 가진 약제의 규제 당국에 의한 승인이 진행되어 기존 요법의 한계를 극복함으로써 시장 성장이 더욱 강화되고 있습니다.

기술과 연구개발의 진보로 보다 새롭고 효율적인 항정신병약가 개발되고 있습니다. 제약기업은 부작용이 적고 효능이 높고 환자의 복약 준수성을 향상시키는 약제의 연구개발에 엄청난 투자를 하고 있습니다. 2025년 9월, H. 룬드벡사와 오츠카 홀딩스 주식회사는 PTSD 성인 환자를 위한 치료제로서 렉수르티(브렉스피프라졸)와 세르트랄린의 병용 요법에 관한 추가 신약 승인 신청(sNDA)에 대해 미국 식품의약국(FDA)으로부터 완전 대응 서한(CRL)을 받았습니다.

2023년 1월, 에자이 주식회사는 알츠하이머병 치료제 레켄비에 대한 FDA의 신속 승인 제도에 의한 승인을 취득했습니다. 신경 질환에 대한 고급 치료 옵션의 도입으로 세계 환자에서 항정신병 약물의 사용이 증가하고 있습니다.

지역별 시장 대시보드
지역별 시장 점유율 분석, 2024년 및 2033년
지역별 시장 : 주요 포인트
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제9장 경쟁 구도

주요 시장 진출기업에 의한 최근의 동향과 영향 분석
기업/경쟁의 분류
벤더 상황
기업 프로파일
- H. Lundbeck A/S
- Otsuka Pharmaceutical Co., Ltd.
- Janssen Pharmaceuticals, Inc.
- Eli Lilly and Company
- AbbVie, Inc.
- Teva Pharmaceutical Industries Ltd.
- Dr Reddy's Laboratories Ltd.
- Sumitomo Pharma Co., Ltd.
- Alkermes
- Bristol-Myers Squibb Company

SHW

영문 목차

영문목차

Antipsychotic Drugs Market Summary

The global antipsychotic drugs market size was estimated at USD 17.53 billion in 2024 and is projected to reach USD 32.24 billion by 2033, growing at a CAGR of 6.1% from 2025 to 2033. The market is expanding due to the increasing prevalence of mental health disorders, greater awareness, and innovations. Government support, insurance coverage, and the availability of generics are further driving accessibility, especially in emerging markets.

Antipsychotic medications, also known as neuroleptics, are commonly employed to alleviate symptoms linked to psychosis. Antipsychotic medications can effectively decrease and manage various symptoms, such as paranoia and auditory hallucinations, including delusions and hearing voices. Antipsychotic medications work by inhibiting the activity of dopamine and other neurotransmitters in the brain. First and second-generation antipsychotic medications are currently available in the market.

The increasing prevalence of psychotic disorders is expected to drive the demand in the antipsychotic drugs industry. The Schizophrenia burden consistently affects men more than women, and as life expectancy improves regionally, the overall burden of Schizophrenia is expected to grow further. Aging populations also support demand, as conditions such as dementia-related psychosis become more prevalent. Market growth has been reinforced by regulatory approvals of new formulations and novel mechanisms of action, which address limitations of older therapies.

Advancements in technology and research in drug development have also resulted in the creation of newer and more efficient Antipsychotic drugs. Pharmaceutical companies are investing significantly in researching and developing medications with fewer side effects, higher effectiveness, and enhanced patient adherence. In September 2025, H. Lundbeck A/S and Otsuka Holdings Co., Ltd received a Complete Response Letter (CRL) from the FDA for a supplemental New Drug Application (NDA) for REXULTI (brexpiprazole) in combination with sertraline for treating adults with PTSD.

In January 2023, Eisai Co., Ltd. obtained FDA approval for Leqembi through the Accelerated Approval Pathway for Alzheimer's disease treatment. The introduction of advanced pharmaceutical choices for neurological disorders is increasing the use of antipsychotic drugs among patients worldwide.

Global Antipsychotic Drugs Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antipsychotic drugs market report based on disease, drug, therapeutic class, distribution channel, and region:

Disease Outlook (Revenue, USD Million, 2021 - 2033)
Schizophrenia
Bipolar Disorder
Unipolar Depression
Dementia
Others
Drug Outlook (Revenue, USD Million, 2021 - 2033)
Risperidone
Quetiapine
Olanzapine
Aripiprazole
Brexpiprazole
Paliperidone Palmitate
Others
Therapeutic Class Outlook (Revenue, USD Million, 2021 - 2033)
First Generation
Second Generation
Third Generation
Distribution Channel Class Outlook (Revenue, USD Million, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Disease
- 1.2.2. Drug
- 1.2.3. Therapeutic class
- 1.2.4. Distribution channel
- 1.2.5. Regional scope
- 1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Disease outlook
- 2.2.2. Drug outlook
- 2.2.3. Therapeutic class
- 2.2.4. Distribution Channel
- 2.2.5. Regional outlook
2.3. Competitive Insights

Chapter 3. Antipsychotic Drugs Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
3.3. Antipsychotic Drugs Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape

Chapter 4. Antipsychotic Drugs Market: Disease Estimates & Trend Analysis

4.1. Disease Segment Dashboard
4.2. Antipsychotic Drugs Market: Disease Movement Analysis
4.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
- 4.3.1. Schizophrenia
  - 4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.3.2. Bipolar Disorder
  - 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.3.3. Unipolar Depression
  - 4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.3.4. Dementia
  - 4.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.3.5. Others
  - 4.3.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Antipsychotic Drugs Market: Drugs Estimates & Trend Analysis

5.1. Drugs Segment Dashboard
5.2. Antipsychotic Drugs Market: Drug Movement Analysis
5.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Drugs, 2021 to 2033 (USD Million)
- 5.3.1. Risperidone
  - 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.3.2. Quetiapine
  - 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.3.3. Olanzapine
  - 5.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.3.4. Aripiprazole
  - 5.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.3.5. Brexpiprazole
  - 5.3.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.3.6. Paliperidone Palmitate
  - 5.3.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.3.7. Others
  - 5.3.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Antipsychotic Drugs Market: Therapeutic Class Estimates & Trend Analysis

6.1. Therapeutic Class Segment Dashboard
6.2. Antipsychotic Drugs Market: Therapeutic Class Movement Analysis
6.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Therapeutic Class, 2021 to 2033 (USD Million)
- 6.3.1. First Generation
  - 6.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 6.3.2. Second Generation
  - 6.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 6.3.3. Third Generation
  - 6.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Antipsychotic Drugs Market: Distribution Channel Estimates & Trend Analysis

7.1. Distribution Channel Segment Dashboard
7.2. Antipsychotic Drugs Market: Distribution Channel Movement Analysis
7.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
- 7.3.1. Hospital Pharmacies
  - 7.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 7.3.2. Retail Pharmacies
  - 7.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 7.3.3. Online Pharmacies
  - 7.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Antipsychotic Drugs Market: Regional Estimates & Trend Analysis

8.1. Regional Market Dashboard
8.2. Regional Market Share Analysis, 2024 & 2033
8.3. Continuous bioprocessing market by Region: Key Takeaways
8.4. North America
- 8.4.1. U.S.
  - 8.4.1.1. Key country dynamics
  - 8.4.1.2. Regulatory framework/ reimbursement structure
  - 8.4.1.3. Competitive scenario
  - 8.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.2. Canada
  - 8.4.2.1. Key country dynamics
  - 8.4.2.2. Regulatory framework/ reimbursement structure
  - 8.4.2.3. Competitive scenario
  - 8.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.3. Mexico
  - 8.4.3.1. Key country dynamics
  - 8.4.3.2. Regulatory framework/ reimbursement structure
  - 8.4.3.3. Competitive scenario
  - 8.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
8.5. Europe
- 8.5.1. UK
  - 8.5.1.1. Key country dynamics
  - 8.5.1.2. Regulatory framework/ reimbursement structure
  - 8.5.1.3. Competitive scenario
  - 8.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.2. Germany
  - 8.5.2.1. Key country dynamics
  - 8.5.2.2. Regulatory framework/ reimbursement structure
  - 8.5.2.3. Competitive scenario
  - 8.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.3. France
  - 8.5.3.1. Key country dynamics
  - 8.5.3.2. Regulatory framework/ reimbursement structure
  - 8.5.3.3. Competitive scenario
  - 8.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.4. Italy
  - 8.5.4.1. Key country dynamics
  - 8.5.4.2. Regulatory framework/ reimbursement structure
  - 8.5.4.3. Competitive scenario
  - 8.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.5. Spain
  - 8.5.5.1. Key country dynamics
  - 8.5.5.2. Regulatory framework/ reimbursement structure
  - 8.5.5.3. Competitive scenario
  - 8.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.6. Denmark
  - 8.5.6.1. Key country dynamics
  - 8.5.6.2. Regulatory framework/ reimbursement structure
  - 8.5.6.3. Competitive scenario
  - 8.5.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.7. Sweden
  - 8.5.7.1. Key country dynamics
  - 8.5.7.2. Regulatory framework/ reimbursement structure
  - 8.5.7.3. Competitive scenario
  - 8.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.8. Norway
  - 8.5.8.1. Key country dynamics
  - 8.5.8.2. Regulatory framework/ reimbursement structure
  - 8.5.8.3. Competitive scenario
  - 8.5.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
8.6. Asia Pacific
- 8.6.1. Japan
  - 8.6.1.1. Key country dynamics
  - 8.6.1.2. Regulatory framework/ reimbursement structure
  - 8.6.1.3. Competitive scenario
  - 8.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.2. China
  - 8.6.2.1. Key country dynamics
  - 8.6.2.2. Regulatory framework/ reimbursement structure
  - 8.6.2.3. Competitive scenario
  - 8.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.3. India
  - 8.6.3.1. Key country dynamics
  - 8.6.3.2. Regulatory framework/ reimbursement structure
  - 8.6.3.3. Competitive scenario
  - 8.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.4. Australia
  - 8.6.4.1. Key country dynamics
  - 8.6.4.2. Regulatory framework/ reimbursement structure
  - 8.6.4.3. Competitive scenario
  - 8.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.5. South Korea
  - 8.6.5.1. Key country dynamics
  - 8.6.5.2. Regulatory framework/ reimbursement structure
  - 8.6.5.3. Competitive scenario
  - 8.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.6. Thailand
  - 8.6.6.1. Key country dynamics
  - 8.6.6.2. Regulatory framework/ reimbursement structure
  - 8.6.6.3. Competitive scenario
  - 8.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
8.7. Latin America
- 8.7.1. Brazil
  - 8.7.1.1. Key country dynamics
  - 8.7.1.2. Regulatory framework/ reimbursement structure
  - 8.7.1.3. Competitive scenario
  - 8.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.2. Argentina
  - 8.7.2.1. Key country dynamics
  - 8.7.2.2. Regulatory framework/ reimbursement structure
  - 8.7.2.3. Competitive scenario
  - 8.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
8.8. MEA
- 8.8.1. South Africa
  - 8.8.1.1. Key country dynamics
  - 8.8.1.2. Regulatory framework/ reimbursement structure
  - 8.8.1.3. Competitive scenario
  - 8.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8.2. Saudi Arabia
  - 8.8.2.1. Key country dynamics
  - 8.8.2.2. Regulatory framework/ reimbursement structure
  - 8.8.2.3. Competitive scenario
  - 8.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8.3. UAE
  - 8.8.3.1. Key country dynamics
  - 8.8.3.2. Regulatory framework/ reimbursement structure
  - 8.8.3.3. Competitive scenario
  - 8.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8.4. Kuwait
  - 8.8.4.1. Key country dynamics
  - 8.8.4.2. Regulatory framework/ reimbursement structure
  - 8.8.4.3. Competitive scenario
  - 8.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
- 9.3.1. Key company heat map analysis, 2024
9.4. Company Profiles
- 9.4.1. H. Lundbeck A/S
  - 9.4.1.1. Company overview
  - 9.4.1.2. Financial performance
  - 9.4.1.3. Product benchmarking
  - 9.4.1.4. Strategic initiatives
- 9.4.2. Otsuka Pharmaceutical Co., Ltd.
  - 9.4.2.1. Company overview
  - 9.4.2.2. Financial performance
  - 9.4.2.3. Product benchmarking
  - 9.4.2.4. Strategic initiatives
- 9.4.3. Janssen Pharmaceuticals, Inc.
  - 9.4.3.1. Company overview
  - 9.4.3.2. Financial performance
  - 9.4.3.3. Product benchmarking
  - 9.4.3.4. Strategic initiatives
- 9.4.4. Eli Lilly and Company
  - 9.4.4.1. Company overview
  - 9.4.4.2. Financial performance
  - 9.4.4.3. Product benchmarking
  - 9.4.4.4. Strategic initiatives
- 9.4.5. AbbVie, Inc.
  - 9.4.5.1. Company overview
  - 9.4.5.2. Financial performance
  - 9.4.5.3. Product benchmarking
  - 9.4.5.4. Strategic initiatives
- 9.4.6. Teva Pharmaceutical Industries Ltd.
  - 9.4.6.1. Company overview
  - 9.4.6.2. Financial performance
  - 9.4.6.3. Product benchmarking
  - 9.4.6.4. Strategic initiatives
- 9.4.7. Dr Reddy's Laboratories Ltd.
  - 9.4.7.1. Company overview
  - 9.4.7.2. Financial performance
  - 9.4.7.3. Product benchmarking
  - 9.4.7.4. Strategic initiatives
- 9.4.8. Sumitomo Pharma Co., Ltd.
  - 9.4.8.1. Company overview
  - 9.4.8.2. Financial performance
  - 9.4.8.3. Product benchmarking
  - 9.4.8.4. Strategic initiatives
- 9.4.9. Alkermes
  - 9.4.9.1. Company overview
  - 9.4.9.2. Financial performance
  - 9.4.9.3. Product benchmarking
  - 9.4.9.4. Strategic initiatives
- 9.4.10. Bristol-Myers Squibb Company
  - 9.4.10.1. Company overview
  - 9.4.10.2. Financial performance
  - 9.4.10.3. Product benchmarking
  - 9.4.10.4. Strategic initiatives

한글목차

항정신병약 시장 요약

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 항정신병약 시장의 변수, 동향, 범위

제4장 항정신병약 시장 : 질환별 추정·동향 분석

제5장 항정신병약 시장 : 약제별 추정·동향 분석

제6장 항정신병약 시장 : 치료 클래스별 추정·동향 분석

제7장 항정신병약 시장 : 유통 채널별 추정·동향 분석

제8장 항정신병약 시장 : 지역별 추정·동향 분석